Multimodal nocturnal seizure detection in a residential care setting

Citation for published version (APA):

DOI:
10.1212/WNL.0000000000006545

Document status and date:
Published: 20/11/2018

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:
• A submitted manuscript is the author's version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us:
openaccess@tue.nl
providing details. We will immediately remove access to the work pending the investigation of your claim.
Multimodal nocturnal seizure detection in a residential care setting
A long-term prospective trial

Johan Arends, MD, PhD, Roland D. Thijs, MD, PhD, Thea Gutter, MSc, Constantin Ungureanu, MSc, PhD, Pierre Cluitmans, MSc, PhD, Johannes Van Dijk, PhD, Judith van Andel, MD, PhD, Francis Tan, MD, Al de Weerd, MD, PhD, Ben Vledder, Wytske Hofstra, MD, PhD, Richard Lazeron, MD, PhD, Ghislaine van Thiel, PhD, Kit C.B. Roes, PhD, Frans Leijten, MD, PhD, and the Dutch Tele-Epilepsy Consortium


Abstract

Objective
To develop and prospectively evaluate a method of epileptic seizure detection combining heart rate and movement.

Methods
In this multicenter, in-home, prospective, video-controlled cohort study, nocturnal seizures were detected by heart rate (photoplethysmography) or movement (3-D accelerometry) in persons with epilepsy and intellectual disability. Participants with >1 monthly major seizure wore a bracelet (Nightwatch) on the upper arm at night for 2 to 3 months. Major seizures were tonic-clonic, generalized tonic >30 seconds, hyperkinetic, or others, including clusters (>30 minutes) of short myoclonic/tonic seizures. The video of all events (alarms, nurse diaries) and 10% completely screened nights were reviewed to classify major (needing an alarm), minor (needing no alarm), or no seizure. Reliability was tested by interobserver agreement. We determined device performance, compared it to a bed sensor (Emfit), and evaluated the caregivers’ user experience.

Results
Twenty-eight of 34 admitted participants (1,826 nights, 809 major seizures) completed the study. Interobserver agreement (major/no major seizures) was 0.77 (95% confidence interval [CI] 0.65–0.89). Median sensitivity per participant amounted to 86% (95% CI 77%–93%); the false-negative alarm rate was 0.03 per night (95% CI 0.01–0.05); and the positive predictive value was 49% (95% CI 33%–64%). The multimodal sensor showed a better sensitivity than the bed sensor (n = 14, median difference 58%, 95% CI 39%–80%, p < 0.001). The caregivers’ questionnaire (n = 33) indicated good sensor acceptance and usability according to 28 and 27 participants, respectively.

Conclusion
Combining heart rate and movement resulted in reliable detection of a broad range of nocturnal seizures.
Methods

Study design
We conducted a multicenter, prospective, cohort study.

Standard protocol approvals, registrations, and patient consents
The trial (Dutch Trial Registry 4115) was approved by the Medical Research Ethics Committee of the University Medical Center Utrecht in the Netherlands.

Participants
The study population consisted of adults with an intellectual disability (ID) who were included if they had a history of >1 major nocturnal seizure per month and resided in a long-term facility of 1 of the participating epilepsy centers between September 1, 2015, and January 9, 2017. Persons with a movement disorder, pacemaker, or skin pigmentation were excluded (the last because we had no proof that the green light–based plethysmography would work on pigmented skin). All participants or their legal guardians provided written informed consent.

Outcome

Primary
The primary outcome was performance in terms of sensitivity, positive predictive value (PPV), false-negative alarm rate (FNAR), and false-positive alarm rate (FPAR) of the multimodal sensor to detect major seizures.

Secondary
The secondary outcomes were a comparison with the bed sensor, the quality of the signal data, factors influencing algorithm performance, and user experience of the caregivers.

Study phases and assessments
In the first (training) phase of the study, 20 participants were monitored for ≈3 months to test the multimodal sensor (skin contact, skin reactions, ease of use, quality of signals) and to improve the hardware and the detection algorithm. In the second phase, the multimodal sensor generated alarms. Fourteen of these participants entered the second phase. Fourteen new participants (group 2) were added and, after a period of 1 to 2 weeks to become accustomed to the bracelet, were monitored for 2 to 3 months.

The multimodal sensor was compared with the bed sensor in 14 participants who already used the bed sensor before the start of the trial.

Sensor measurements
The bracelet (figure 1) was fixed around the upper arm on the side where the seizures were known to start. The multimodal sensor settings could not be externally modified. Amplitude and duration of the piezoelectric Emfit bed sensor were optimized according to the manual before the start of the trial. It detects the clonic part of a motor seizure by producing an alarm after a rhythmic movement of 2 to 3 Hz during 10 to 16 seconds.

Data and events collection
The HR and ACC signals and the online alarms of the multimodal sensor were wirelessly transmitted to a base station that was connected to a Macbook computer that also was connected to an infrared-sensitive video camera. HR and ACC signals were analyzed offline during phase 1 and online.

Glossary

ACC = accelerometry; CI = confidence interval; FNAR = false negative alarm rate; FPAR = false-positive alarm rate; GT = long generalized tonic; HK = hyperkinetic; HR = heart rate; ID = intellectual disability; OM = other major; PPV = positive predictive value; SUDEP = sudden unexpected death in epilepsy; TC = tonic-clonic.
participated in a blinded interobserver agreement evaluation at the end of phase 1. For this test, 50 random events were selected. The Fleiss $\kappa$\textsuperscript{18} between major or no major (i.e., minor or no) seizures was the primary outcome measure; secondary outcomes were whether there was a TC seizure and the overall agreement.

**Signal processing**

We analyzed the performance, (sensitivity + PPV)/2, of the algorithm in the preparation phase 1 with the 14 first participants. The algorithm with the best performance was chosen and fixed for use at the start of phase 2, the prospective trial.

The detection algorithm (see flowchart of the detection algorithm in figure 4 available from Dryad, doi.org/10.5061/dryad.553f4q3) is executed in the sensor.

In the algorithm, HR values are determined and updated every second on the basis of a 5-minute average of past individual peak-to-peak intervals. Simultaneously, a signal quality index is calculated for each HR value that is based on the plethysmographic waveform. If the signal quality index is adequate (>80%), seizure detection starts with a slope and absolute value threshold (tachycardia), depending on the prior baseline HR. If the signal quality index is not adequate, HR is considered unreliable, and only the ACC algorithm is used for detection. The ACC sensor module provides a motion and a position indicator every second. The motion is a representation of the motor rhythmicity during a seizure and is based on the number of zero crossings for each axis per second. The position parameter indicates whether the patient is lying, sitting, or standing. The function of the position parameter is to prevent alarms when the patient is sitting or standing.

An alarm is generated only if the position indicates lying and the threshold for HR (slope or tachycardia) is exceeded or the motion value stays above threshold for at least 15 seconds.

**Performance**

A video event was considered true positive when an alarm was given within 3 minutes before or 5 minutes after the start of a major seizure to allow detection of focal bilateral spreading seizures or atypical seizure types. False-positive detections <3 minutes apart were scored as 1. Performance (sensitivity, PPV, FNAR, and FPAR) was calculated per patient and for each sensor (multimodal and bed sensor). FNAR and FPAR were calculated per standardized night (i.e., number of false-negative or false-positive alarms per 8 hours).

We assessed the relative contributions of HR (slope and tachycardia) and ACC to the true and false detections because many false-positive detections may occur when based on HR alone.\textsuperscript{16}

We assessed the percentage of good signal quality of the HR (>80%) during all recorded nights.
**Questionnaires**

All caregivers (including those of dropouts) completed a questionnaire designed for this trial that was based on our value-sensitive design study\(^1\)\(^6\) to evaluate the usability of the multimodal sensor.

**Study size and bias**

The sample size of 30 adults was chosen to obtain acceptable confidence limits of the sensitivity and was based on preliminary results of the preceding EEG/video study.\(^9\) The required sample size for the comparison of the multimodal sensor with the Emfit bed sensor was at least 37 seizures per group, assuming a sensitivity of 80% for the multimodal sensor and 60% for the bed sensor (\(β = 0.80, α = 0.05\)). Because the participants should have >1 seizure per month and the trial lasted 2 to 3 months, we expected >35 seizures. Because of the unknown variability of the number of seizures per participant, a more appropriate estimation of the required number of participants was not possible.

Inclusion bias was avoided by using a low inclusion threshold and only a few necessary exclusion criteria.

**Data presentation and statistics**

Sensitivity and PPV are used as performance measures mostly at the population level and generally not at an individual level. The strongly varying number of seizures per participant led us to calculate detection rates as averages per person and then use these figures for the descriptive group statistics. Rank-order, nonparametric statistics were used to estimate the median value of parameter values across the average of inpatient parameters. The reported 95% confidence intervals (CIs) for the median estimate were calculated from the parameter value that is associated with the closest rank to the rounded \(n \times 0.5 \pm 0.98 \times \sqrt{n}\) rank value. This formula is based on the assumption that the ranks of the patient samples are normally distributed. This assumption is valid for \(n\) larger than or on the order of \(n = 20\). However, to remain consistent across the presented results, we also used this method for \(n < 20\).

The 95% CIs for the interobserver agreement scores were calculated with AgreeStat2015.6 (Advanced Analytics LLC, Gaithersburg, MD). The data are presented as population tables. All individual scores, 2 boxplots, and 1 scatterplot are shown in tables 6 through 17 and figures 3 through available from Dryad (doi.org/10.5061/dryad.553f4q3). The performance of the multimodal system is shown in figure 5 available from Dryad (doi.org/10.5061/dryad.553f4q3). The performance of the multimodal sensor is summarized in table 2.

The following group comparisons were made: multimodal vs bed sensor and the results of the 10% screening vs the 90% nonscreening nights. To test for inclusion bias, group 1 (who already participated in phase 1) was compared to group 2 (those entering the trial in phase 2).

Participants who withdrew from the trial were not replaced.

Statistical tests were performed with the Mann-Whitney test for unpaired data or the Wilcoxon signed-rank test for paired data with \(α\) (2-sided) < 0.05.

**Data availability**

Individual deidentified participant data are available in the supplemental material. Requests for reanalysis of the complete database, which contains privacy-sensitive information, will have to be approved by the Medical Research Ethics Committee of the University Medical Center Utrecht and the members of the Dutch Tele-Epilepsy Consortium. Data availability is limited by exclusive rights for LivAssured with regard to commercial applications.

**Results**

**Participants and demography**

During phase 1, 4 withdrawals and 2 exclusions occurred (figure 2 and table 6 available from Dryad, doi.org/10.5061/dryad.553f4q3).

Demographic and clinical characteristics of the participants entering phase 2 are presented in table 1. All persons had a generalized or combined generalized/focal type of epilepsy with >1 seizure type.

**Interobserver agreement**

The agreement between major and other or no seizures was substantial (\(κ = 0.77, 95\% CI 0.65–0.89\)). We also found a substantial agreement between TC and all other major seizure types (GT, HK, OM) (\(κ = 0.62, 95\% CI 0.43–0.80\)). The overall agreement between all seizure types (TC, GT, HK, OM, minor, no seizure) was 0.61 (95% CI 0.51–0.71). All individual scores are shown in table 8 available from Dryad (doi.org/10.5061/dryad.553f4q3).

**Performance of the multimodal system**

A graphic representation of the output of the multimodal sensor is shown in figure 5 available from Dryad (doi.org/10.5061/dryad.553f4q3). The performance of the multimodal sensor is summarized in table 2.

One participant had no major seizures all. In 2 others who had 3 major seizures, the seizures were not detected. Three participants had >1 false-positive alarm per night (6.3, 3.6, and 3.2), accounting for 75% of all false alarms (data available from Dryad, table 9, doi.org/10.5061/dryad.553f4q3). Minor seizures accounted for 26% (368 of 1,402) of the false-positive alarms (data available from Dryad, table 15).

The median FNAR was low (0.03 per night). These false-negative alarms were calculated over the reported events. Comparison of this result with the data of the completely screened nights (table 2) did not reveal any statistically significant difference. The FPAR showed a high variability.
Groups 1 and 2 showed a comparable performance (table 2) despite the fact that the algorithm was fitted to group1 (median sensitivity 86% for both groups, PPV 43% for group 1 and 49% for group 2).

Comparison with the bed sensor
In the group who used the multimodal device and the bed sensor (n = 14), the total number of observed nights was 1,097, and 508 major seizures were recorded. The multimodal device generated 877 alarms; the bed sensor, 303. Ten of the 14 patients with both sensors belonged to group 1 with a longer observation period (3 vs 2 months).

The sensitivity of the bed sensor (median 21%) was significantly lower compared to the multimodal one (median 85%) (table 3). In 2 participants, no PPV difference could be calculated because no alarms were emitted by either 1 or both sensors. PPV tended to be higher for the bed sensor (median 82%) than for the multimodal sensor (median 56%), but the difference did not reach statistical significance (p = 0.90). The bed sensor missed more seizures than the multimodal sensor, with a median FNAR of 0.28 per night vs 0.04 for the multimodal sensor.

Quality of the sensor data
A good signal quality was obtained in 94% of total recording time for HR and up to 100% for ACC. Signal quality could be diminished due to a loss of contact between the bracelet and the skin or by contamination of the plethysmography signal with movement artifacts. No complete nights were excluded because of poor signal quality because a good signal quality of HR and ACC was required per protocol before the recording was started.

Factors influencing algorithm performance

**HR or ACC detection**
We analyzed how HR and ACC contributed to the performance of the algorithm. The critical modality for the true-positive detections was HR (median detection percentage
92%, 95% CI 63%–96%), while ACC accounted for only 8% (95% CI 0%–16%) of the detections. HR was always the critical modality for the false-positive detections because the ACC modality had no false-positive detections.

### Seizure type

The distribution of the detected major seizure types for the multimodal sensor was 48% for TC, 21% for GT, 24% for HK, and 7% for OM. TC seizures were well detected by the multimodal sensor (median detection rate 0.96). The other seizure types were somewhat less well detected (median detection rates between 0.73 and 0.89) (table 4).

### Bed sensor

The bed sensor detected a minority of all major seizure types (medians between 0.00 for OM and 0.30 for HK seizures), including the TC type (0.14). We did not expect this because the bed sensor records the length of rhythmic movements and assumes TC seizure to be present if the length of this rhythmic movement exceeds a programmable value between 10 and 16 seconds.

### Outcomes of questionnaires

An assessment questionnaire was designed that addressed the key aspects of the multimodal sensor that were identified through a process of value-sensitive design. Thirty-three respondents (30 nurses, 2 parents, and 1 not specified), for the 28 participants in phase 2 and for 5 of the 6 excluded participants, completed the questionnaire (table 5).

Caregivers indicated that the sensor implementation facilitated a more timely response to urgent situations, while the burden of

---

**Table 2** Performance of the multimodal sensor

<table>
<thead>
<tr>
<th></th>
<th>Total (n ≤ 28)</th>
<th>Group 1 (n = 14)</th>
<th>Group 2 (n = 14)</th>
<th>10% Screening (n ≤ 28)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median ±95% CI</td>
<td>Median ±95% CI</td>
<td>Median ±95% CI</td>
<td>Median ±95% CI</td>
</tr>
<tr>
<td>Nights, n</td>
<td>54 ±45–82</td>
<td>90 ±48–98</td>
<td>46 a ±33–64</td>
<td>6 ±5–9</td>
</tr>
<tr>
<td>Major seizures, n</td>
<td>14 ±10–26</td>
<td>30 ±13–72</td>
<td>11 a ±2–14</td>
<td>1 ±1–3</td>
</tr>
<tr>
<td>Major seizures per night, n</td>
<td>0.29 ±0.14–0.41</td>
<td>0.40 ±0.14–0.71</td>
<td>0.22 ±0.02–0.33</td>
<td>0.17 ±0.0–0.38</td>
</tr>
<tr>
<td>Alarms, n</td>
<td>30.5 ±14–44</td>
<td>53 ±22–109</td>
<td>14 a ±3–35</td>
<td>3 ±1–5</td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>86 ±77–93</td>
<td>86 ±64–94</td>
<td>86 ±80–92</td>
<td>100 ±50–100</td>
</tr>
<tr>
<td>PPV, %</td>
<td>49 ±33–64</td>
<td>53 ±10–94</td>
<td>49 ±29–56</td>
<td>60 ±0–83</td>
</tr>
<tr>
<td>FNAR per night</td>
<td>0.03 ±0.01–0.05</td>
<td>0.04 ±0.00–0.21</td>
<td>0.03 ±0.00–0.04</td>
<td>0.00 ±0.00–0.17</td>
</tr>
<tr>
<td>FPAR per night</td>
<td>0.25 ±0.04–0.35</td>
<td>0.26 ±0.03–0.72</td>
<td>0.18 ±0.02–0.35</td>
<td>0.04 ±0.00–0.33</td>
</tr>
</tbody>
</table>

**Table 3** Comparison of the multimodal and the bed sensor

<table>
<thead>
<tr>
<th></th>
<th>Multimodal sensor</th>
<th>Bed sensor</th>
<th>Multimodal – bed sensor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median ±95% CI</td>
<td>Median ±95% CI</td>
<td>Median ±95% CI</td>
</tr>
<tr>
<td>Nights, n</td>
<td>79 ±48–99</td>
<td>79 ±48–99</td>
<td></td>
</tr>
<tr>
<td>Major seizures, n</td>
<td>21 ±12–72</td>
<td>21 ±12–72</td>
<td></td>
</tr>
<tr>
<td>Major seizures per night, n</td>
<td>0.34 ±0.12–0.71</td>
<td>0.34 ±0.12–0.71</td>
<td>0.34 ±0.12–0.71</td>
</tr>
<tr>
<td>Alarms, n</td>
<td>46 ±13–108</td>
<td>22 ±1–30</td>
<td></td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>85 ±71–93</td>
<td>21 ±6–32</td>
<td>58 a ±39–80</td>
</tr>
<tr>
<td>PPV, %</td>
<td>56 ±34–94</td>
<td>82 ±30–90</td>
<td>2 ±(52)–7</td>
</tr>
<tr>
<td>FNAR per night</td>
<td>0.04 ±0.00–0.17</td>
<td>0.28 ±0.08–0.54</td>
<td>(0.21) a ±0.49–0.11</td>
</tr>
<tr>
<td>FPAR per night</td>
<td>0.23 ±0.00–0.59</td>
<td>0.03 ±0.00–0.21</td>
<td>0.11 ±(0.11)–0.45</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI = confidence interval; FNAR = false-negative alarm rate; FPAR = false-positive alarm rate; PPV = positive predictive value.

For a boxplot and scatterplot of the differences, and individual data, see information available from Dyad (doi.org/10.5061/dryad.553f4q3).

a p < 0.05 (group 1 vs group 2).
care remained unchanged. A considerable number of sensor problems was reported. All of these were transient or have been resolved. Skin irritation occurred during the preparatory phase of the trial and was eliminated by removing the paint on the surface of the sensor and by avoiding the bracelet being fixed too tightly. Nonfitting of the bracelet was prevented by changing the texture and attachment of the elastic band. Nonacceptance by the participant occurred twice; it was temporary in one and led to exclusion in another. The majority of caregivers (n = 20) experienced more freedom, but only a minority (10) thought the participants had gained more autonomy.

In addition, respondents gave the user-friendliness of the multimodal sensor a grade of 7.3 on a scale from 1 to 10 (1 being the lowest user-friendliness). With regard to privacy, respondents graded the level of invasion of privacy as 4.2 on the same scale (1 being the lowest level of invasion).

**Discussion**

This long-term prospective study demonstrates that it is possible to reliably detect major motor seizures using a combination of HR and ACC parameters. The multimodal sensor

| Table 4 Detection rates of multimodal and bed sensor for each seizure type |
|-----------------------------|-------------------|-----------------|-----------------|-----------------|
| Detection rate per seizure type | TC | GT | HK | MO |
| **Multimodal sensor** | | | | |
| No. | 22 | 11 | 5 | 14 |
| Median | 0.96 | 0.89 | 0.73 | 0.84 |
| −95% CI | 0.80 | 0.33 | 0.50 | 0.50 |
| +95% CI | 1.00 | 1.00 | 1.00 | 1.00 |
| **Bed sensor** | | | | |
| No. | 12 | 7 | 3 | 5 |
| Median | 0.14 | 0.17 | 0.30 | 0.00 |
| −95% CI | 0.06 | 0.00 | 0.27 | 0.00 |
| +95% CI | 0.31 | 0.38 | 0.32 | 0.43 |

Abbreviations: CI = confidence interval; GT = long generalized tonic (>30 seconds); HK = hyperkinetic; OM = other major; TC = tonic-clonic.

| Table 5 Assessment of key valued aspects of the multimodal sensor |
|-----------------------------|------------------|---------|---------|---------|
| Questionnaire for parents/caregivers | | | | |
| Aspect | Item | Yes, n | No, n | Other, n | Not applicable/no answer, n |
| Care | Helps caregiver provide better care | 22 | 5 | 5 | 1 |
| | More timely care | 18 | | | |
| | Increased understanding of daytime behaviors | 4 | | | |
| | Helps relieve burden of caregiving | 7 | 26 | — | — |
| Sensor | Sensor is accepted by the patient | 28 | 2 | 2 | 1 |
| | Problems with the sensor | 13 | 8 | | 12 |
| | Skin irritation | 3 | | | |
| | Armband does not fit | 5 | | | |
| | Poor connection or signal reception | 5 | | | |
| Usability | Sufficient technical support | 27 | 1 | 5 | — |
| | Sufficient with installation, not for use | 2 | | | |
| | Sufficient for use, not with installation | 3 | | | |
| Autonomy | Offers more autonomy to people with epilepsy | 10 | 13 | — | 10 |
| | Offers caregiver more freedom | 20 | 11 | — | 2 |
has a much better sensitivity than the bed sensor and a comparable PPV. It is well accepted, is easy to use, and provides accurate measurements over time. The device can also be used to monitor epilepsy treatment.

Conventional studies have been testing rhythmic movements in epilepsy monitoring units where the majority of patients are screened for epilepsy surgery. These patients usually have focal seizures of temporal lobe origin that evolve into classic TC seizures. The bed sensor and other systems based on movement detection perform well under these circumstances, but their performance deteriorates in the specific population of this trial. This relatively low performance of the bed sensor is in accordance with the results of the ACC part of our algorithm. Accelerometric research and clinical experience indicate that people with ID and epilepsy show more atypical seizure patterns: different sequences of tonic and clonic phases may occur in changing order, and status epilepticus may develop from seizure types other than classic TC. This may explain the low performance of the bed sensor in this population, although the sensor had been selected before the trial as the best alternative.

Despite the low performance, bed sensors and other rhythmic movement–based sensors remain useful: they may yield accurate alarms if rhythmic movements last for 10 to 16 seconds or longer and the sensitivity is adapted to avoid false positives. The low performance of the bed sensor confirms the need to include signal modalities other than ACC in seizure detection. Physiologically, complementary signal combinations are as follows: HR or skin conductance (both expressions of autonomic function), EMG (for tonic phases of seizures), and video or audio detection (based on specific sounds). We chose HR, the fastest signal other than EEG, that is considered an adequate alternative to EEG. Measurements of HR in smartwatches are less reliable because of the oval form of the wrist, which may prevent optimal body contact. Under controlled conditions, smartwatches record useful signals up to 88% of the time, while our device showed good signal quality for 94%, i.e., half the error rate (6% vs 12%). Results of the rhythmic movement–based seizure detection at the wrist by smartwatches are disappointing and in line with our results for the bed sensor. Contrary to smartwatches, our device does not need a smartphone interface. Its DECT technology provides a larger wireless range (50 m) than Bluetooth (10 m). Respiratory function (depressed postictal blood oxygen saturation) is also used for seizure detection with fairly good results, but the obtrusiveness and false-positive responses make it less useful for long-term detection at home. The plethysmographic signal also has the potential to detect breathing rate.

We introduced the concept of major seizures as a representation of clinical urgency of seizures. Major seizures are specified by medical professionals as seizure semiology, which includes loss of consciousness, falls, long duration, intense movements, respiratory problems, cluster or status, salivation/vomiting, oxygen drop, migraine, or visual problems. All 3 seizure types (TC, GT, HK) and the less well-defined class OM are characterized by >1 of these elements and were adequately detected by our device as a result of the introduction of the HR signal. The ACC module of the device detected a minority of the seizures compared to the HR module. This is due to the high threshold imposed by the requirement of 15-second continuous rhythmic movement, causing seizures with a short clonic phase to be missed, but also a PPV of 0%. A shorter duration will increase the detection rate of the ACC module but also will introduce false alarms. Regarding the PPV of the multimodal device, we have to consider different factors than for the bed sensor. The specific nature of the HR response and the atypical evolution of motor seizures in people with epilepsy and ID may lower the PPV for the multimodal device, while the required long duration of the clonic part of the seizures may result in a higher PPV for the bed sensor. Together, these may explain why a slightly higher PPV was found for the bed sensor, although this was not statistically significant. The PPV results for group 1, in whom the algorithm was developed, and group 2 were similar, suggesting that our results are not liable to overfitting.

Although generic “1 size fits all” solutions are feasible, personalized algorithms need to be explored in future. ACC and HR seem complementary: contrary to rhythmic movements, the HR increase is not linked to 1 particular seizure expression but is the result of the sympathetic response to seizures. We did not systematically study the interactions between the HR and ACC signals. HR increases may cause false-positive detections in persons with high resting HRs or strong excitability such as children. Our HR-related algorithm might benefit from self-learning algorithms accounting for physiologic arousals and varying baseline levels and requires further study. Adding other signal modalities to the 2 used in this study may also help to improve our algorithms.

The decision to consider minor seizures as false-positive results was made to avoid too many alarms for the caregiver and to limit the alarms to those requiring immediate care. While these minor seizures could be valuable to improve the reliability of the seizure counts, we currently have no algorithm that can discriminate these events from nonepileptic arousals or movements during sleep. In our study population, focal seizures other than HK occurred relatively rarely. Thus, we cannot predict whether the HR and motor patterns in these seizures will be detected. Novel algorithms might benefit from analysis of HR variability to discriminate between epileptic and nonepileptic seizures or to use HR variability as a marker of cardiac arousability. Daytime use of detectors when the higher level of activity may cause more false positives is also an important issue.

The multimodal sensor might be of help in preventing SUDEP. A recent guideline of the American Association of Neurology indicates that clinicians may use a remote listening device to reduce SUDEP risk in high-risk individuals (Level C). Although comparative studies are lacking, combining HR and ACC seems more effective for detecting major
Seizures because of the shortcomings of current audio detection.\textsuperscript{14,15} Seizure diaries are an inaccurate, subjective method for counting seizures.\textsuperscript{35} Our device may offer a more objective method for nocturnal seizure counting not only to use in clinical trials but also to measure the efficacy of individual therapy. The multimodal sensor may provide data about the urgency of seizures because we found indications that the height and duration of the HR increase correlate with the subjectively estimated urgency of clinical seizures.\textsuperscript{36} Our study has a number of limitations. First, we did not use video-EEG as the gold standard. The decision to use video alone was imposed by the long duration of the monitoring (\textgeq3 months) and the residential use outside the hospital. The substantial interobserver agreement confirms that this decision was justified. Second, the exclusion of persons with abnormal movements prevents extrapolation of the results of this study to this group, consisting mainly of persons with perinatal damage leading to choreatiform movement patterns. Third, because of the current intensity of the light-emitting source, we could not reliably measure the light reflections in people with dark-colored skin. This can be overcome by adaptive light intensity. Fourth, the assessment of quality of life is important for measuring the economic gain. In this population, however, the standard tools for quality of life are not adequate: the low intellectual level (moderate to severe impairment) prevents adequate communication and is often associated with immobility and other handicaps. The results of the value-based scale (gain in care, freedom of movement for the caregiver, and presumed autonomy for the user) were counterbalanced by the reported mild interference with the privacy. These results, however, cannot be compared with other studies because of the new methodology.\textsuperscript{16} Fifth, interference with privacy needs to be explored further because video verification may be used more often in the relatively small number of users with many (false) alarms.

Author contributions

Study funding
This study was funded by the following grants: A Disease Management Chronic Diseases grant from the Dutch National Science Foundation (NWO-ZonMW) No. 300040003, the NUTS-Ohra Foundation No. 1203-050, and the Dutch Epilepsy Foundation for extra material costs. LivAssured, the company developing the Nightwatch device, has obtained an exclusive license to implement or use the data in the future for commercial purposes or in commercial enterprises in exchange for a percentage of the revenue for the institutes. None of the authors has shares in the aforementioned company nor in the aforementioned institutes, nor has any of them received nor will any of them receive any compensation referring to future sales of the Nightwatch. The Dutch Tele-Epilepsy Consortium will receive more research funds from the institutes as a consequence of this license.

Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication history
Received by Neurology January 2, 2018. Accepted in final form August 9, 2018.

References
Multimodal nocturnal seizure detection in a residential care setting: A long-term prospective trial
Johan Arends, Roland D. Thijs, Thea Gutter, et al.
Neurology 2018;91:e2010-e2019 Published Online before print October 24, 2018
DOI 10.1212/WNL.0000000000006545

This information is current as of October 24, 2018

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/91/21/e2010.full

References
This article cites 32 articles, 3 of which you can access for free at:
http://n.neurology.org/content/91/21/e2010.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Clinical trials Observational study (Cohort, Case control)
http://n.neurology.org/cgi/collection/clinical_trials_observational_study_cohort_case_control
Epilepsy monitoring
http://n.neurology.org/cgi/collection/epilepsy_monitoring_

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise